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Fibroblast growth factor 21 (FGF21) has beneﬁcial effects of improving the plasma glucose and lipid
proﬁles in diabetic rodents. Here, we investigated carbohydrate response element binding protein
(ChREBP) involvement in the regulation of FGF21 mRNA expression in liver. Glucose stimulation
and adenoviral overexpression of dominant active ChREBP increased FGF21 mRNA. Consistently,
adenoviral expression of dominant negative Mlx inhibited glucose induction of FGF21 mRNA. Fur-
thermore, deletion studies of mouse FGF21 gene promoter (2000 to +65 bp) revealed a glucose
responsive region between 74 and 52 bp. These ﬁndings suggest that FGF21 expression is regu-
lated by ChREBP.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction We have reported that ChREBP, a glucose activated transcrip-Fibroblast growth factor 21 (FGF21) belongs to the ﬁbroblast
growth factor (FGF) family involved in cell growth, cell differenti-
ation, and embryonic development [1]. FGF21 has been found to
have multiple beneﬁcial effects in treatment of metabolic syn-
drome including obesity as well as diabetes mellitus [2]. Trans-
genic mice with FGF21 overexpression are resistant to diet-
induced obesity and glucose intolerance [3]. Treatment with
FGF21 induces energy expenditure and improves glucose intoler-
ance, hypertriglycemia and hepatic steatosis in ob/ob mice [4]. In
human, serum FGF21 levels in diabetic or obese individuals are
higher than normal, and are signiﬁcantly correlated with adiposity,
plasma fasting insulin and the triglyceride concentration [5]. Fur-
thermore, Akt signaling and PPAR- increases FGF21 mRNA expres-
sion in muscle and adipose tissue, respectively [6]. These ﬁndings
suggest that FGF21 is increased in adaptation to increased body
weight and energy intake.chemical Societies. Published by E
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a).tion factor, regulates lipogenic enzyme gene expression and is in-
volved in the development of metabolic syndrome [7,8].
Transactivity of ChREBP is increased in genetically obese mice,
and gene deletion of ChREBP improves metabolic disorders such
as fatty liver and glucose intolerance [9]. Recently, some groups
have reported that overexpression of dominant negative Mlx,
which forms a heterodimer with ChREBP, inhibits glucose medi-
ated FGF21 gene expression in rat hepatocytes [10]. These ﬁndings
suggest that glucose activation of ChREBP might be involved in
FGF21 mRNA expression.
In this study, we tested whether glucose stimulation or activa-
tion of ChREBP could increase FGF21 mRNA expression in rat hepa-
tocytes We also performed a deletion study of mouse FGF21 gene
promoter and identiﬁed the glucose responsive region. Our ﬁnd-
ings demonstrate that glucose stimulation via ChREBP activation
induces FGF21 gene expression in rat primary hepatocytes and that
FGF21 has an important role in glucose and lipid homeostasis.
2. Materials and methods
2.1. Materials, tissue materials, hepatocyte isolation, and Taqman PCR
analysis
The protocols for all animal experiments were approved by the
Institutional Animal Care and Use Committee of Gunma Universitylsevier B.V. All rights reserved.
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tocytes were isolated and cultured from 6 weeks age male Wistar
rats (SLC) as previously described [11,12].
2.2. Construction of plasmid and adenovirus vectors
pcDNA-daChREBP, Ad-daChREBP, Ad-dnMlx, and pGL4 TK RLuc
were used previously [11,12]. The series of pGL3-mFGF21 vectors
were constructed as follows: a fragment representing 2000,
1205, 1012, 797, 317, 197, 100, 67, and 40 bp (posi-
tion 2000/+65, 1205/+65, 1012/+65, 797/+65, 317/+65,
197/+65, 100/+65, 67/+65, and 40/+65 relative to the tran-
scription start site of mouse FGF21 of the native 50 sequence ﬂank-
ing the mouse FGF21 gene were cloned upstream of the luciferase
gene in pGL3 basic vector. The series of pGL3 promoter mFGF21
vectors were constructed as follows: a fragment representing
100/30, 90/40, 67/30, 100/67 bp (position 100/
30, 90/40, 67/30, 100/67 relative to the transcription
start site of mouse FGF21 gene, respectively) of the native 50 se-
quence ﬂanking the mouse FGF21 gene were cloned upstream of
TK promoter in pGL3 promoter vector. A fragment 3XFGF21
E1(101/80 bp) or 3XFGF21 E2 (74/52 bp) was cloned up-
stream of TK promoter in pGL3 promoter vector. Mouse FGF21
cDNA expressing adenovirus (Ad-FGF21) was constructed as fol-
lows: Mouse FGF21 full-length cDNA was cloned using Prime Star
DNA polymerase reagents. PCR fragment was ligated into pENTR
vector (Invitrogen). Recombination of adenovirus and pENTR
FGF21 vector was performed to produce Ad-FGF21 vectors accord-
ing to manufacture’s protocol. All plasmid and adenovirus vectors
were veriﬁed by sequencing analysis.
2.3. Treatment with recombinant adenovirus in rat hepatocytes
Rat primary hepatocytes were cultured in six-well plates in
2 ml DMEM medium. After 2, 10, and 50 m.o.i. of adenovirus bear-
ing GFP, dominant active ChREBP (daChREBP) dominant negative
Mlx (dnMlx), or FGF21 was infected into hepatocytes for 2 h, media
were removed and infected hepatocytes were incubated in media
with 2.5 or 25 mM glucose concentration for 18 h. Cells were then
collected and used for RNA extraction, cDNA synthesis and RT-PCR
analysis as previously described [11,12].
2.4. Mammalian transfection and reporter assay
Rat primary hepatocytes were cultured in six-well plates in
2 ml DMEM without antibiotics. The cells were transfected with
Lipofectamine2000 (10 ll), the series of pGL3-mFGF21 (3.6 lg),
and the pGL4 TK RLuc vector (0.4 lg) [12]. After 24 h of incubation
at 2.5 or 25 mM glucose concentration, the cells were collected and
used to measure luciferase activity (Dual Luciferase assay system;
Promega, Madison, WI) according to manufacture’s protocol. To
determine glucose dependency on the glucose response region in
mouse FGF21 gene promoter, cells were transfected with 3.1 lg
of pGL3 promoter 3XFGF21 E1, 3XFGF21 E2, or 3XLPK ChoRE vec-
tors, 0.4 lg of pGL4-RLuc-TK vectors and 0.5 lg of pcDNA6.2
empty vector or daChREBP vector. After 24-h incubation with var-
ious glucose concentrations, the cells were collected for measure-
ment of luciferase activity.
2.5. Data presentation and statistical methods
All data are expressed as means ± S.D. The listed n values repre-
sent the number of single experiments performed (each experi-
ment was duplicated). Comparisons between two groups were
performed by student t-test and comparison between multiplegroups was performed by Tukey–Kramer test. A value of P < 0.05
was regarded as signiﬁcant.3. Results
3.1. The role of ChREBP in glucose mediated FGF21 gene expression
As FGF21 mRNA is expressed mainly in islets and liver
(Fig. S1A), we examined FGF21 mRNA expression in liver of dia-
betic model mice. FGF21 mRNA levels in 6 weeks age male STZ
mice and ob/ob mice were 1.1- and 2.5-fold higher than that in
6 weeks age C57BL/6J mice, respectively (Fig. S1B). To verify that
glucose increased FGF21 mRNA expression, we examined the ef-
fect of glucose and ChREBP on FGF21 mRNA expression. High glu-
cose stimulation increased FGF21 mRNA expression in a time
dependent manner (Fig. 1A). These ﬁndings suggest that a metab-
olite in the glycolytic and pentose pathway induces FGF21 mRNA
expression. Adenoviral overexpression of daChREBP increased
FGF21 mRNA expression in a dose-dependent manner (Fig. 1B).
Furthermore, Mlx is an obligate heterodimer partner of ChREBP
that is required for binding and activation of glucose-regulated
gene expression [11]. In accord with Fig. 1B, dnMlx successfully
inhibited glucose induction of FGF21 mRNA gene expression in
rat primary hepatocytes (Fig. 1C). Similarly, siRNA against ChREBP
inhibited not only ChREBP mRNA but also glucose mediated
FGF21, liver type pyruvate (LPK), and fatty acid synthase (FASN)
gene expression in rat primary hepatocytes (Fig. S1C). Thus, trans-
activation of ChREBP induces FGF21 mRNA expression in
hepatocytes.3.2. Identiﬁcation of glucose response region in mouse FGF21 gene
promoter
Deletion studies of mouse FGF21 gene promoter showed that
a region between 100 and 67 bp is critical for the glucose
response to FGF21 mRNA induction (Fig. 2A). We tested in detail
putative glucose response elements in mouse FGF21 promoter
(between 200 and +0 bp) (Fig. 2B). Fig. 2B shows that a
region between 90 and 40 bp is critical for the glucose
response to FGF21 mRNA expression. We also determined which
putative E-Box (E1: 101/80 bp and E2: 74/52 bp) functions
as the glucose response element (Supplementary Fig. S2). In
accord with Fig. 2A and B, the E2 element (74/52 bp) is shown
to possesses glucose responsiveness or ChREBP mediated activa-
tion of FGF21 mRNA expression (Fig. 2C). We also tested the
glucose response to luciferase activity in pGL3-3XFGF21 E2 vec-
tor. Compared with pGL3 FGF21 2 kbp vector, luciferase activi-
ties were similarly dependent on the glucose concentration
(Fig. 2D).3.3. Effect of FGF21 overexpression on ChREBP and expression of its
target genes in rat hepatocytes
FGF21 lowers plasma glucose and increases glucose uptake in
muscle and adipose tissue, but its role in liver is unclear. Because
the FGF21 signaling cascade requires both FGF receptors (FGFRs)
and beta-Klotho [13,14], we conﬁrmed that all of the FGFRs were
present in both mouse liver and rat hepatocytes and beta-Klotho
was detected in mouse livers (Fig. S3A and B) [14]. We then tested
whether FGF21 affects glucose mediated LPK and FASN mRNA
expression in rat hepatocytes. Glucose induction of LPK and FASN
mRNA expression in rat hepatocytes infected in a dose-dependent
manner with Ad-FGF21 were unchanged as compared with those
in untreated hepatocytes (Fig. 3).
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Fig. 1. (A) Glucose stimulates increased FGF21 mRNA expression in rat hepatocytes. Isolated hepatocytes were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
including several concentrations of glucose for 24 h and collected at the indicated hours for Taqman RT-PCR analysis. (B) Adenoviral overexpression of dominant active
ChREBP increased FGF21 mRNA expression in rat hepatocytes. Isolated hepatocytes were infected with 2, 10, and 50 m.o.i. of Ad-daChREBP for 2 h. After culture in DMEM
with 2.5 mM glucose concentration for 18 h, the cells were collected for Taqman RT-PCR analysis. Data represent means ± S.D. (C) Adenoviral overexpression of dominant
negative Mlx increased FGF21 mRNA expression in rat hepatocytes. Isolated hepatocytes were infected with 2, 10, and 50 m.o.i. of Ad-dnMlx for 2 h. After culture in DMEM
with 2.5 or 25 mM glucose concentration for 18 h, the cells were collected for Taqman RT-PCR analysis. Values represent means ± S.D. At most points, the error bars are too
small to be shown.
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In this study, we show that FGF21 is a target gene of ChREBP
in rat primary hepatocytes. Moreover, we identiﬁed a glucose
response region located between 74 and 52 bp in the FGF21
promoter. Adenoviral delivery of FGF21 cDNA into rat primary
hepatocytes was found not to directly affect glucose induction
of LPK and FASN mRNA expression in rat hepatocytes.
Thus, FGF21 is directly regulated by the glucose activated tran-
scription factor ChREBP, and ChREBP is not directly regulated
by FGF21.
As found in a previous study, FGF21 mRNA is most abundant in
mouse islets and liver, in which ChREBP is also highly expressed
(Fig. S1A) [2,15]. FGF21 mRNA is more highly upregulated in ob/
ob mice, but is only slightly induced in STZ mice (Fig. S1B). In addi-
tion, ob/ob mice show hyperinsulinemia and hyperglycemia, while
STZ mice show hypoinsulinemia and hyperglycemia (Fig. S1B).
Considered together with our previous ﬁnding that ChREBP activa-tion requires insulin action, glucose-stimulated FGF21 mRNA
expression may well require insulin action [12,16]. In accord with
the data shown in Fig. 1A, overexpression of daChREBP induced
FGF21 mRNA expression and overexpression of dnMlx inhibited
glucose-induced FGF21 mRNA expression (Fig. 1B and C). More-
over, siRNA against ChREBP suppressed glucose induction of
FGF21 mRNA expression in rat primary hepatocytes (Fig. S1C).
These ﬁndings indicate that glucose activation of ChREBP induces
hepatic FGF21 mRNA expression. In fact, some groups have re-
ported that plasma FGF21 concentrations and hepatic FGF21
mRNA expression in obese and diabetic animal models are much
higher than those in control lean animals [5]. ChREBP is remark-
ably activated in livers from these diabetic animals, further sug-
gesting that glucose activation of ChREBP induces FGF21 mRNA
expression. Moreover, satiety signaling such as PPAR- and Akt sig-
naling induces FGF21 mRNA expression [6,16–18]. Thus, FGF21
gene expression is regulated by satiety signals such as glucose
and insulin.
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Fig. 2. (A) Deletion studies of mouse FGF21 gene promoter. Isolated hepatocytes were cultured in six-well dishes and transfected with the series of pGL3-mFGF21 vector
(3.6 lg) and pGL4 TK RLuc (0.4 lg) using Lipofectamine2000 (10 ll). After 24 h incubation in DMEM including 2.5 or 25 mM glucose concentrations, luciferase activities were
measured using Dual Luciferase assay kit. (B) Detailed analysis of the carbohydrate response region in mouse FGF21 promoter. Cells were transfected with the series of pGL3
promoter mFGF mutants (3.6 lg), and pGL4 TK RLuc (0.4 lg) using Lipofectamine2000 (10 ll). After 24 h incubation in DMEM including 2.5 or 25 mM glucose concentrations,
luciferase activities were measured using Dual Luciferase assay kit. (C) Reporter analysis of pGL3 promoter 3XFGF21 E2 (74/52 bp). Rat primary hepatocytes were
transfected with 3.1 lg of pGL3 promoter 3XFGF21 E2 (74/52p), 3XFgf21 E1 (101/80 bp), or 3XLPK ChoRE vectors, 0.4 lg of pGL4-RLuc-TK vectors and 0.5 lg of
pcDNA6.2 empty vector or pcDNA6.2 daChREBP vector. Cells were incubated at 2.5 or 25 mM glucose for 24 h and collected for the measurement of luciferase activities. (D)
Glucose dependent activation of pGL3 promoter 3XFGF21 E2 (74/52 bp) vector and pGL3-mFGF21 2 kbp. Cells were transfected with 3.6 lg of pGL3 promoter 3XFGF21
E2 (74/52 bp) vector or pGL3-mFGF21 2 kbp and 0.4 lg of pGL4-RLuc-TK vector. Cells were incubated at several glucose concentrations for 24 h and collected for
measurement of luciferase activities. Values represent means ± S.D. At most points, the error bars are too small to be shown. *P < 0.05 vs. Ad-GFP.
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diet-induced obese mice reduces hepatic ChREBP-target gene
expression [4,19]. The FGF21 signaling cascade requires the
FGF21 receptor complex, FGFR, and an adapter-like molecule,
beta-Klotho [14]. Beta-Klotho and FGFR1-4 are abundantly ex-
pressed in liver, adipose tissues, and pancreas [14,15,20–22]. In
our experiments, all FGFRs were detectable in mouse liver and
rat hepatocytes and beta-Klotho was detected only in mouse li-
ver (Fig. S3A and B). The sequence of rat beta-Klotho cDNA re-
mains unknown and we could not check beta-Klotho mRNA
expression in rat primary hepatocytes. We then tested whether
FGF21 directly affects glucose activation of ChREBP-target gene
expressions such as LPK and FASN. We found that FGF21 had
no signiﬁcant effects on the expression of these genes in rat
hepatocytes (Fig. 3). GLUT1 gene expression, an FGF21 target,
was also unchanged in rat hepatocytes infected by Ad-FGF21(data not shown). Consistent with these data, some groups have
reported that FGF21 does not act on mouse primary hepatocytes
and rat hepatoma cell lines, even in the presence of beta-Klotho
and FGFRs [14,23,24]. In contrast, some groups reported the
opposite evidences that FGF21 is active in cells of hepatic origin
[25]. The presence of beta-Klotho in rat primary hepatocytes re-
mains unknown and it will be needed to further investigate the
direct action of FGF21 in liver. In conclusion, these results indi-
cate that FGF21 suppresses ChREBP transactivity at least indi-
rectly by lowering plasma glucose concentrations in the whole
body.
In conclusion, glucose induces FGF21 mRNA expression via
transactivation of ChREBP, indicating that both FGF21 and ChREBP
are involved in the regulation of glucose and lipid homeostasis in
liver. Thus, FGF21 may well be a useful drug in the treatment of
diabetes and obesity.
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Fig. 3. Adenoviral overexpression of FGF21 did not inhibit LPK and FASN mRNA.
Adenovirus expressing either GFP or FGF21 was transduced into rat hepatocytes at
m.o.i. of 2, 10, and 50. As control, recombinant adenovirus expressing GFP was used
at m.o.i. of 50. Two h after infection, the cells were cultured in DMEM including 2.5
or 25 mM glucose for an additional 18 h. Total RNA was extracted from hepatocytes,
and RT-PCR analysis was performed. Values represent means ± S.D. At most points,
the error bars are too small to be shown.
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